Priyadarshini Pathak, MBBS

Articles

Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

September 4th 2025

Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.

ASCO 2025 Recap: Top Takeaways in Pancreatic Cancer

August 6th 2025

Panelists discuss how promising developments at ASCO 2025 include novel immunotherapy combinations, KRAS G12D-targeted therapies in phase 3 trials, tumor treating fields for locally advanced disease, and the importance of addressing nutrition and quality of life alongside pharmacologic advances.

NAPOLI: Using Liposomal Irinotecan (with 5-FU/LV) in the Second-Line Setting in mPDAC and Beyond

July 30th 2025

Panelists discuss how the NAPOLI-1 trial established 5-FU/leucovorin plus liposomal irinotecan as the standard second-line therapy for patients who received gemcitabine-based first-line treatment, though patient selection remains challenging.

Sequencing mPDAC Therapy Beyond First Line: Clinical and Patient-Centered Strategies

July 30th 2025

Panelists discuss how second-line therapy sequencing involves using the backbone not received in first-line (5-FU or gemcitabine-based), with increased emphasis on quality of life discussions and the importance of early tumor sequencing for potential targeted therapies.

Comparing FFX (or mFFX) and Gem-NabP: What Clinical Practice Tells Us

July 23rd 2025

Panelists discuss how real-world data suggest similar efficacy between NALIRIFOX and FOLFIRINOX, and how sequential therapy approaches using doublets don’t appear superior to up-front triplet regimens for appropriate patients.

mPDAC Frontline Therapy: Real-World Evidence and Emerging Trial Data From ASCO 2025

July 23rd 2025

Panelists discuss how NALIRIFOX differs from modified FOLFIRINOX primarily in lower neuropathy rates due to reduced oxaliplatin dosing, higher diarrhea rates, and lower neutropenia, while UGT1A1 testing is generally not required up front.

FFX (or mFFX) vs NALIRIFOX: Managing Toxicity and Genetic (UGT1A1*28) Dose Considerations in mPDAC

July 16th 2025

Panelists discuss how recent ASCO data showed long-term responders on NALIRIFOX were younger, fitter patients with lower disease burden who could tolerate treatment longer, reinforcing the strategy of dose modifications to maintain patients on therapy.

NAPOLI 3 Trial Deep Dive: ASCO 2025 Updated OS Analysis

July 16th 2025

Panelists discuss how the PRODIGE-4 and NAPOLI-3 trials differed in patient populations, age limits, and comparator arms, leading to similar regimens with dosage modifications that have become standard practice.

Aligning Goals in mPDAC: Shared Decision-Making in First-Line Therapy

July 9th 2025

Panelists discuss how patient choice and long-term toxicity considerations, particularly neuropathy differences between NALIRIFOX and FOLFIRINOX, influence treatment decisions while managing patient expectations about stable disease being a positive outcome.

mPDAC: Historical Milestones and Selecting the Right First-Line Regimen

July 9th 2025

Panelists discuss how the evolution of pancreatic cancer treatment has progressed since 2011 with key trials like PRODIGE-4 (FOLFIRINOX) and NAPOLI-3 (NALIRIFOX), and how clinicians choose between regimens based on patient characteristics and adverse effect profiles.

Locally Advanced Pancreatic Cancer: Treatment Approaches and Regimen Selection

June 30th 2025

Panelists discuss how treatment decisions for locally advanced pancreatic cancer should consider systemic therapy followed by radiation, with triplet regimens preferred for younger patients with good performance status, while acknowledging the limited evidence base requiring extrapolation from metastatic data.

Expert Perspectives: 55-Year-Old Woman Presenting With Locally Advanced Pancreatic Cancer: Next Steps

June 30th 2025

Panelists discuss how to approach a 55-year-old woman with locally advanced pancreatic cancer involving portal vein invasion, emphasizing the importance of staging, performance status assessment, and systemic chemotherapy as first-line treatment.